BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.
1008 Data Byte RADx
BioCentury & Infogram

Finance

Data Bytes: RADx funding recipients

By Danielle Golovin, Staff Writer
Oct 8, 2020 | 11:52 PM GMT

NIH and BARDA granted six additional awards to COVID-19 diagnostics developers this week, bringing its total investment in the RADx Initiative for scale-up and manufacturing of new COVID-19 testing technologies to $476.4 million across 22 projects.

Launched in April, the Rapid Acceleration of Diagnostics (RADx) Initiative is a $500 million national technology development competition designed to fuel the development of rapid and easy-to-use COVID-19 tests.

The most recent contracts, issued via RADx’s third round of funding, were awarded to Ellume USA LLC, Luminostics Inc., Quanterix Corp. (NASDAQ:QTRX),  Flambeau Diagnostics, Visby Medical Inc. and Ubiquitome.

Three of the six new contracts will support development of antigen tests. A study published in medRxiv this week by Becton Dickinson and Co. (NYSE:BDX) and Johns Hopkins University scientists suggests antigen tests for COVID-19 do a better job of predicting which patients are infectious than PCR tests.

How to gain access

Continue reading with a
two-week free trial.